SC verdict on NJAC: Govt questions transparency of collegium system

October 16, 2015

Bengaluru, Oct 16: Expressing "surprise" over Supreme Court's decision to strike down a new law to appoint judges to the higher judiciary, government today questioned the transparency of the old collegium system which has been revived with the verdict.

sadananda gowda

Law Minister D V Sadananda Gowda said the next course of action will be decided after consultations with Prime Minister Narendra Modi and Cabinet colleagues.

"We are surprised by the verdict of the Supreme Court," Gowda told reporters in Bengaluru on the apex court striking down the Constitutional Amendment Act and an enabling law to establish the National Judicial Appointments Commission(NJAC) to recommend transfer of High Court judges and their elevation to the Supreme Court.

Telecom Minister Ravi Shankar Prasad and Attorney General Mukul Rohatgi questioned the transparency of the collegium system which the law sought to replace.

With the NJAC Act struck down, the appointments to the higher judiciary will be made by the collegium system which ended in April when the government notified the new law.

"The Supreme Court has said that from November 3 it will hear the issue of improving the collegium system. It shows that there was something wrong in the collegium system," Prasad told reporters in Delhi.

Rohatgi expressed similar sentiments after the landmark verdict. "Appointments will continue to be made in an opaque system where all stakeholders will not have a voice. The collegium system is not found in the Constitution and according to me, the system is not appropriate," he said.

"Whether collegium system will be changed or not is in the wisdom of the court. But if it needs to be improved, it means it wasn't correct in the first place," he said.

While Gowda and Prasad, a former Law Minister, said the government will come out with a structured response after going through the order, the AG ruled out the option of seeking review in the matter saying, "I don't think it is a case for review at all as the verdict is detailed and runs into over a thousand pages."

Gowda said he would decide on the future course of action after consulting the Prime Minister, his senior Cabinet colleagues and legal experts.

"The will of the people can be represented through the Parliament, through the legislature only, it cannot be brought to the notice of the whole world by some other means," Gowda said.

Parliamentary Affairs Minister M Venkaiah Naidu said there was a unanimous support for the bills in the Lok Sabha and the Rajya Sabha during voting.

"20 state assemblies had ratified it...the principal author of the 1993 Supreme Court judgement (which led to the collegium system) (late) Justice J S Verma had also suggested a serious rethink on the collegium system and so had Justice V R Krishna Iyer," Prasad said.

Naidu said the will of the people was brought before the Court, noting that the Lok Sabha and Rajya Sabha had supported the bill besides 20 state legislatures had also ratified the constitutional amendment.

"It is a legislation passed by Parliament and ratified by legislative assemblies of states after much discussion. The collective wisdom of Parliament has gone into it and the mood of the people is reflected in the Bill," he said, adding that government will deliberate on the future course of action on the issue soon.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 23,2020

New Delhi, Jul 23: With the highest single-day spike of 45,720 cases, India's coronavirus count crossed 12 lakh mark on Thursday.

The Union Ministry of Health and Family Welfare informed that 1,129 deaths were recorded in the last 24 hours.

The total number of coronavirus cases stand at 12,38,635 including 4,26,167 active cases, 7,82,606 cured/discharged/migrated. The cumulative toll has reached 29,861 deaths.

Maharashtra has reported 3,37,607 cases, highest in the country followed by Tamil Nadu with 1,86,492 cases. Delhi coronavirus count has reached 1,26,323 cases.

According to the Indian Council of Medical Research (ICMR), 1,50,75,369 samples were tested till July 22 out of which 3,50,823 samples were tested yesterday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 9,2020

Kolkata, Mar 9: A diabetic man died in the isolation ward of a hospital in West Bengal's Murshidabad on Sunday, a day after he was admitted there with suspected symptoms of coronavirus following his return from Saudi Arabia.

According to doctors, he was admitted to the hospital with fever, cough and cold.

Though test results of his blood and swab samples for novel coronavirus were awaited, it can be said that he died probably of diabetes, Director of Health Services Ajay Chakraborty told PTI.

"The man was highly diabetic and was on insulin. He returned home from Saudi Arabia and had no money to take insulin for the last three to four days.

"He was also suffering from fever, cough and cold. He was admitted to the isolation ward of the Murshidabad Medical College and Hospital yesterday and died today," the health services director said.

"We are waiting for the results of medical tests. The possibility of his death due to novel coronavirus infection is remote," he said.

However, precautions will be taken during the last rites of the victim according to the directives set by the central and state governments for patients who die of the virus, another senior official said.

"Family members will not be allowed to touch the body since the man had been suffering from cough and breathlessness. Those performing his last rites will be given protective gear, masks and gloves. Though test results are yet to be known, we do not want to take any chance," he said.

Meanwhile, the state health department has issued a directive to all private medical facilities to create a system for assessing all patients at admission allowing early recognition of possible COVID-19 infection and immediate isolation of patients with suspected novel coronavirus infection in an area separate from other patients.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 30,2020

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.